secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2026-10-06T20:57:49+00:00
Accession:  0001193125-26-415730
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 5.02, 5.03, 5.07, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Quince Therapeutics stockholders approve 2026 equity plans, charter amendment, and Series C conversion proposals
--------------------------------------------------------------------------------

- Stockholders approved the 2026 Equity Incentive Plan with an initial reserve of 821,872 shares plus up to 1,377,845 returning shares, and the 2026 ESPP with 142,045 shares.
- The charter amendment increased authorized common stock from 250,000,000 to 275,000,000 shares and was filed in Delaware on Oct. 6, 2026.
- At the Oct. 6, 2026 special meeting, 611,465 of 1,017,063 outstanding shares, or 60%, were present; all five presented proposals were approved.
- Proposal 1, covering Series C preferred conversion and warrants/options, was approved 180,550 to 5,742, with 162,971 shares excluded; it may result in a change of control under Nasdaq Rule 5635(b).
- The 2026 Plan reserve automatically increases 5% annually from Jan. 1, 2027 through Jan. 1, 2036; the ESPP increases by the lesser of 1% or two times its initial reserve.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526415730/0001193125-26-415730-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526415730/d115238d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-415730

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer